Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance
NCT05707182Phase 1Withdrawn
- Sponsor
- University of Alabama at Birmingham
- Start
- Apr 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of fludeoxyglucose f 18 in prostate cancer (PCa), sponsored by University of Alabama at Birmingham. Primary endpoint: Number of lesions detected in total on the participants' mpMRI exams. Planned start Apr 2025; status: withdrawn.
02
Drugs
fludeoxyglucose f 18
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05707182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05707182.